Literature DB >> 14988439

Dietary soy beta-conglycinin (7S globulin) inhibits atherosclerosis in mice.

Michael R Adams1, Deborah L Golden, Adrian A Franke, Susan M Potter, Houston S Smith, Mary S Anthony.   

Abstract

Although beta-conglycinin (7S globulin), a major soy storage protein, stimulates the expression of LDL receptors and the degradation of LDL by hepatocytes in vitro, the in vivo effects of dietary beta-conglycinin on the cardiovascular system are unknown. We assessed the effects of dietary beta-conglycinin and other soy peptide fractions on the development of atherosclerosis in atherosclerosis-susceptible mice. At 6 wk of age, male and ovariectomized female apolipoprotein (apo) E-null mice and LDL receptor-null, apoB transgenic mice were assigned randomly to treatment groups that differed only in the source of dietary protein: 1) casein/lactalbumin, 2) isoflavone-containing soy protein isolate, 3) beta-conglycinin, 4) glycinin (11S globulin, another major soy storage protein), 5) beta-conglycinin-devoid soy protein, and 6) W008 (a peptide fraction produced by hydrolysis and precipitation of soy protein isolate). After 4 mo, aortic atherosclerosis (cholesteryl ester content) and plasma lipoprotein cholesterol concentrations were quantified using GLC. Relative to mice fed casein/lactalbumin-based diets, the extent of atherosclerosis was reduced in ovariectomized female mice fed all soy protein-containing diets. Relative to mice fed isoflavone-containing soy protein isolate, atherosclerosis was reduced only in mice fed the beta-conglycinin-containing diet. Mean reductions were 39 and 67% (all P <0.05) in male and ovariectomized female apoE null mice and 66% (P < 0.05) in male LDL receptor null mice. These effects were unrelated to variation in isoflavone content of the protein source and only minimally related to plasma lipoprotein cholesterol concentrations. We conclude that a diet rich in beta-conglycinin has atheroprotective effects that greatly exceed those of isoflavone-containing soy protein isolate and do not depend on LDL receptors or influences on plasma lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14988439     DOI: 10.1093/jn/134.3.511

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  15 in total

Review 1.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  Soy protein containing isoflavones favorably influences macrophage lipoprotein metabolism but not the development of atherosclerosis in CETP transgenic mice.

Authors:  Leiko Asakura; Patrícia M Cazita; Lila M Harada; Valéria S Nunes; Jairo A Berti; Alessandro G Salerno; Daniel F J Ketelhuth; Magnus Gidlund; Helena C F Oliveira; Eder C R Quintão
Journal:  Lipids       Date:  2006-07       Impact factor: 1.880

3.  Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria.

Authors:  Juquan Jiang; Lynnette C Johnson; John Knight; Michael F Callahan; Travis J Riedel; Ross P Holmes; W Todd Lowther
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-12-29       Impact factor: 4.052

4.  Hydroxyproline metabolism in mouse models of primary hyperoxaluria.

Authors:  John Knight; Ross P Holmes; Scott D Cramer; Tatsuya Takayama; Eduardo Salido
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-21

5.  The α' subunit of β-conglycinin and various glycinin subunits of soy are not required to modulate hepatic lipid metabolism in rats.

Authors:  Cynthia Chatterjee; Jiajie Liu; Carla Wood; Christine Gagnon; Elroy R Cober; Judith A Frégeau-Reid; Stephen Gleddie; Chao-Wu Xiao
Journal:  Eur J Nutr       Date:  2017-03-21       Impact factor: 5.614

6.  Replacement of dietary soy protein isolate with concentrates of soy 7S or 11S globulin has minimal or no effects on plasma lipoprotein profiles and biomarkers of coronary risk in monkeys.

Authors:  Michael R Adams; Mary S Anthony; Haiying Chen; Thomas B Clarkson
Journal:  Atherosclerosis       Date:  2007-03-09       Impact factor: 5.162

7.  Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions.

Authors:  Marguerite A Klein; Richard L Nahin; Mark J Messina; Jeanne I Rader; Lilian U Thompson; Thomas M Badger; Johanna T Dwyer; Young S Kim; Carol H Pontzer; Pamela E Starke-Reed; Connie M Weaver
Journal:  J Nutr       Date:  2010-04-14       Impact factor: 4.798

8.  Reliability of serum and urinary isoflavone estimates.

Authors:  Gary E Fraser; Adrian A Franke; Karen Jaceldo-Siegl; Hannelore Bennett
Journal:  Biomarkers       Date:  2010-03       Impact factor: 2.658

9.  Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Nicholas W Hatch; Sarah J Srodulski; Huei-Wei Chan; Xuan Zhang; Lisa R Tannock; Victoria L King
Journal:  Gend Med       Date:  2012-09-13

10.  Soy protein inhibits inflammation-induced VCAM-1 and inflammatory cytokine induction by inhibiting the NF-κB and AKT signaling pathway in apolipoprotein E-deficient mice.

Authors:  Ramona L Burris; Hang-Pong Ng; Shanmugam Nagarajan
Journal:  Eur J Nutr       Date:  2013-03-07       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.